Inactive Instrument

US Rare Earth Minerals Inc Share Price Other OTC

US9034101082

Biotechnology & Medical Research

End-of-day quote Other OTC Other stock markets
- ^USD	-

15/05	Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
16/04	Bioxytran, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

on all subscriptions*

Last days

Enjoy this offer

* See conditions under "Our services"

Valuation: US Rare Earth Minerals Inc

Market Cap	35.26L 30.39L 27.97L 26.24L 49.28L 33Cr 49.78L 3.31Cr 1.29Cr 16Cr 1.32Cr 1.3Cr 56Cr	P/E Ratio 2024	-5.27x	P/E Ratio 2025	-3.28x
Enterprise Value	42.67L 36.77L 33.84L 31.75L 59.64L 40Cr 60.23L 4Cr 1.56Cr 20Cr 1.6Cr 1.57Cr 68Cr	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	99.38%	Yield 2024 *	-	Yield 2025	-

* Estimated data More valuation ratios

Latest news : US Rare Earth Minerals Inc

15/05	Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
16/04	Bioxytran, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
15/04	Bioxytran, Inc. Auditor Raises 'Going Concern' Doubt	CI
18/03	Bioxytran, Inc. announced that it has received $1.158942 million in funding	CI
05/03	Bioxytran Inc Announces Positive Dose Optimization Results And Advances Toward Phase 3 Registrational Trial For ProLectin-M	CI
02/03	Bioxytran Inc reports positive phase 1b/2a clinical study results for Prolectin-M, broad-range antiviral drug in mild to moderate Covid-19	RE
17/02	Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical Ltd for A-SUQAR Dietary Supplement	CI
11/02	Bioxytran reports positive phase 2 results demonstrating rapid viral clearance with Prolectin-Mbioxytran	RE
11/02	Bioxytran, Inc. Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with Prolectin-Mbioxytran	CI
03/02	Bioxytran, Inc. and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics	CI
15/12	Bioxytran, Inc. Announces Resignation of Anders Utter from Board of Directors and Chair of Audit Committee	CI
15/11	Bioxytran, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
14/11	Bioxytran, Inc. announced that it has received $0.43 million in funding	CI

More news

Press Releases: US Rare Earth Minerals Inc

29/05	Bioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25	AQ
20/03	BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT	AQ
05/03	Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M	AQ
23/02	Bioxytran Initiates Research Collaboration with University of Georgia to Evaluate Drug Candidate's Ability to Block H5N1 Bird Flu Virus	AQ
17/02	Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical LTD for A-SUQAR Dietary Supplement	AQ

More press releases

Managers and Directors: US Rare Earth Minerals Inc

Manager	Title	Age	Since
David Platt CEO	Chief Executive Officer	73	01/09/2018
Ola Soderquist DFI	Director of Finance/CFO	65	01/09/2018
Leslie Ajayi CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Dale Conaway BRD	Director/Board Member	71	02/11/2018
Alan Hoberman BRD	Director/Board Member	73	02/11/2018
David Platt CHM	Chairman	73	01/09/2018

More insiders

Bioxytran, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans. The Company's lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with intended applications, which includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company, through its subsidiary, Pharmalectin Inc., is focused on the development, manufacturing, and commercialization of therapeutic drugs designed to address viral diseases in humans. Pharmalectin Inc. has developed a method designed to reduce the viral load and modulate the immune system using a galectin inhibitor. Its lead drug candidate, named ProLectin-Rx, is a complex polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin.

Employees

Sector

Biotechnology & Medical Research

More about the company

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrows Top Investments!

SEIZE THE OFFER!

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARGENX SE	+0.21%	+0.63%	+57.90%	+109.10%	5.49TCr
WUXI APPTEC CO., LTD.	-0.34%	+3.51%	+45.55%	+40.16%	4.43TCr
BIONTECH SE	+0.29%	+6.20%	-14.80%	-19.65%	2.3TCr
INSMED INCORPORATED	-0.40%	+3.49%	-1.29%	+387.06%	2.11TCr
WUXI BIOLOGICS (CAYMAN) INC.	-2.91%	+0.27%	+13.28%	-36.73%	1.63TCr
GENMAB A/S	-0.85%	-2.11%	+6.92%	-41.11%	1.52TCr
EXELIXIS, INC.	-0.24%	+2.44%	+27.43%	+177.49%	1.33TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.48%	+9.81%	+19.29%	-	1.25TCr
PHARMAESSENTIA CORPORATION	+0.32%	+2.81%	+96.37%	+213.49%	1.12TCr
Average	-0.27%	+2.75%	+27.85%	+103.73%	2.35TCr
Weighted average by Cap.	-0.22%	+2.86%	+32.29%	+95.46%

	2024	2025
Net sales	-	-
Net income	-23.67L -20.4L -18.77L -17.61L -33.08L -22Cr -33.41L -2.22Cr -86.69L -11Cr -88.81L -86.93L -38Cr	-21.23L -18.3L -16.84L -15.8L -29.68L -20Cr -29.97L -1.99Cr -77.77L -9.83Cr -79.67L -77.98L -34Cr
Net Debt	10.89L 9L 9L 8L 15.22L 10Cr 15.37L 1.02Cr 39.89L 5.04Cr 40.86L 40L 17Cr	7L 6L 6L 6L 10.35L 7Cr 10.46L 69.47L 27.13L 3.43Cr 27.8L 27.21L 12Cr

US Rare Earth Minerals Inc Share Price Other OTC

Stocks

US9034101082

Biotechnology & Medical Research

Valuation: US Rare Earth Minerals Inc

Latest news : US Rare Earth Minerals Inc

Press Releases: US Rare Earth Minerals Inc

Managers and Directors: US Rare Earth Minerals Inc

Bio Therapeutic Drugs

Financials

Company Profile